Category: 201150-73-4

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels. 201150-73-4, In a patent£¬Which mentioned a new discovery about 201150-73-4

MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION

The present invention provides compounds of the general formulas I-IX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The present invention further provides treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

201150-73-4, Interested yet? Read on for other articles about 201150-73-4!

Reference£º
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

 

201150-73-4, Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 201150-73-4

PHARMACEUTICAL COMPOUNDS

The invention provides compounds which are pyrimidines of formula (I):wherein R2 is bonded at ring position 2 and -YR1 is bonded at ring position 5 or 6, or YR1 is bonded at ring position 2 and R2 is bonded at ring position 6; R is an indol-4-yl group which is substituted at the 5- or 6-position; either:(a) Y is selected from -O-(CH2)n-, -NH-(CH2)n-, -NHC(O)-(CH2)n and -C(O)NH-(CH2)n- wherein n is 0 or an integer of 1 to 3, and R1 is selected from an unsaturated 5- to 12-membered carbocyclic or heterocyclic group which is unsubstituted or substituted and a group -NR3R4 wherein R3 and R4, which are the same or different, are each independently selected from H, C1-C6 alkyl which is unsubstituted or substituted, C3 – C10 cycloalkyl which is unsubstituted or substituted, -C(O)R, -C(O)N(R)2 and -S(O)mR, or R3 and R4 together form, with the nitrogen atom to which they are attached, a saturated 5-, 6- or 7- membered N-containing heterocyclic group which is unsubstituted or substituted; (b) Y is a direct bond and R1 is selected from an unsaturated 5- to 12-membered carbocyclic or heterocyclic group which is unsubstituted or substituted, and a group -NR3R4 wherein R3 and R4, which are the same or different, are each independently selected from H, C1-C6 alkyl which is unsubstituted or substituted, C3-C10 cycloalkyl which is unsubstituted or substituted, -C(O)R, -C(O)N(R)2 and -S(O)mR; R is selected from H, C1-C6 alkyl, C3-C10 cycloalkyl and a 5- to 12-membered aryl or heteroaryl group, which group is unsubstituted or substituted; and m is 1 or 2; or a pharmaceutically acceptable salt thereof.; These compounds are inhibitors of PO K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PB kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders

201150-73-4, Interested yet? Read on for other articles about 201150-73-4!

Reference£º
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

 

201150-73-4, tert-Butyl 5-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step-1: Synthesis of tert-butyl 5-(2-ethyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-carboxylate To a stirred solution of 2-ethyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one (200 mg, 0.58 mmol, 1.0 eq) in 5 mL of Toluene was added m-CPBA (250 mg, 1.45 mmol, 2.5 eq.) and allowed to stir at rt for 30 minutes. tert-butyl 5-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate (140 mg, 0.58 mmol, 1.0 eq) and DIPEA (300 mg, 2.32 mmol, 4.0 eq) were added and allowed to stir at rt for 1 h. Progress of reaction was monitored by LCMS. After completion of reaction solvent was removed under reduced pressure, residue was diluted with 20 ml of water and extracted with ethyl acetate (50 mL*3). Combined organic layer was washed with water (20 ml*3), dried over anhydrous sodium sulfate and concentrated under reduced pressure. Crude was purified by flash chromatography to obtain 170 mg (53.79%) of tert-butyl 5-(2-ethyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino)-3,4-dihydroisoquinoline-2(1H)-carboxylate., 201150-73-4

The synthetic route of 201150-73-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; giraFpharma LLC; Chakravarty, Sarvajit; PHAM, Son Minh; Kankanala, Jayakanth; AGARWAL, Anil Kumar; PUJALA, Brahmam; SONI, Sanjeev; ARYA, Satish K.; PALVE, Deepak; Gupta, Ashu; KUMAR, Varun; (498 pag.)US2019/106427; (2019); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.201150-73-4,tert-Butyl 5-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate,as a common compound, the synthetic route is as follows.

To a solution of the product from the previous step described above (0.2 g, 0.81 mmol) in THF (5 mL) was added NaH at 0 C. After 15 minutes, CH3I was added and the stirring continued for overnight at room temperature. After completion the reaction mixture was quenched with ice water, extracted with EtOAc (25 mL), dried (Na2S04) and concentrated. The Boc group was removed with 60% TFA-DCM (2 mL) at 0 C to give 110 mg (77.5%) of the final product as a light greenish solid. MS: 177.1 (MH+)., 201150-73-4

As the paragraph descriping shows that 201150-73-4 is playing an increasingly important role.

Reference£º
Patent; INTERMUNE, INC.; ARRAY BIOPHARMA INC.; WO2005/37214; (2005); A2;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

 

201150-73-4, tert-Butyl 5-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 251; tert-butyl 5-{[3-(aminocarbonyl)-6,7-diethoxyquinolin-4-yl]amino}-3, 4- dihydroisoquinoline-2 ( H)-carboxylate ; A mixture of 4-chloro-6, 7-diethoxyquinoline-3-carboxamide (178 mg, 0.61 mmole, prepared according to WO 02/092571), tert-butyl 5-amino-3,4-dihydroisoquinoline-2 (1H)- carboxylate (198 mg, 0.80 mmole), acetic acid (7 Ill) in NMP (3 ml) was heated over night at 110 C. The reaction mixture was cooled, partitioned between ethyl acetate and sodium hydrogen carbonate solution. The organic layer was washed with water, dried over sodium sulfate and concentrated in vacuum. The residue was purified by flash chromatography eluting with dichloromethane/methanol (10: 0.5) to give the title compound as a light brown powder (214 mg, 69 %). 1H NMR (399.99 MHz, DMSO-d6) 8 10.63 (1H, s), 8.84 (1H, s), 8.24 (1H, br s), 7.58 (1H, br s), 7.22 (1H, s), 7.06 (1H, t), 6.95 (1H, d), 6.65 (2H, s), 6.61 (2H, d), 4.53 (2H, s), 4.15 (2H, q), 3.59 (2H, t), 3.49 (2H, d), 2.70 (2H, t), 1.39 (9H, s), 1.36 (3H, t), 1.06 (3H, t). APCI-LC/MS m/z: 507.2 [MH+], 201150-73-4

As the paragraph descriping shows that 201150-73-4 is playing an increasingly important role.

Reference£º
Patent; ASTRAZENECA AB; WO2005/75429; (2005); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.201150-73-4,tert-Butyl 5-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate,as a common compound, the synthetic route is as follows.

Example 34 Synthesis of 2-(5-(6-(2-chlorophenyl)-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]-pyrimidin-2-ylamino)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-3-cyclopropylacrylonitrile Step 1. A solution of 6-(2-chlorophenyl)-8-methyl-2-(methylsulfinyl)pyrido[2,3-d]pyrimidin-7(8H)-one (0.2 g) and tert-butyl 5-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate (0.2 g) in DCM (5 mL) was concentrated to remove DCM. The resulted mixture was then stirred at 140 C. for 0.5 h. LCMS showed completion of reaction and the mixture was purified by preparative TLC to afford tert-butyl 5-(6-(2-chlorophenyl)-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)-3,4-dihydroisoquinoline-2(1H)-carboxylate (150 mg, 48% in yield)., 201150-73-4

201150-73-4 tert-Butyl 5-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate 17750539, aisoquinoline compound, is more and more widely used in various fields.

Reference£º
Patent; Taunton, JR., John William; Brameld, Kenneth Albert; Goldstein, David Michael; Mcfarland, Jesse; Krishnan, Shyam; Choy, Jonathan; US2014/323464; (2014); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

 

201150-73-4, tert-Butyl 5-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

334C. tert-Butyl 5-(2,2,2-trifluoroacetamido)-3,4-dihydroisoquinoline-2(lH)- carboxylate: To a 0 C solution of 334B (1 g, 4.03 mmol) in DCM (25 mL) was added TEA (0.842 mL, 6.04 mmol) and trifluoroacetic anhydride (0.569 mL, 4.03 mmol). The solvent was evaporated and the residue was purified by normal phase column chromatography to give 334C (1.27 g). XH NMR (400MHz, chloroform-d) delta 7.75 (br. s., 1H), 7.59 (d, J = 6.8 Hz, 1H), 7.34 – 7.25 (m, 1H), 7.10 (d, J = 7.6 Hz, 1H), 4.62 (s, 2H), 3.71 (t, J = 5.9 Hz, 2H), 2.71 (t, J = 5.8 Hz, 2H), 1.51 (s, 9H) ppm. MS (ESI) m/z: 244.9 (M+H-Boc)+., 201150-73-4

As the paragraph descriping shows that 201150-73-4 is playing an increasingly important role.

Reference£º
Patent; BRISTOL-MYERS SQUIBB COMPANY; PINTO, Donald J.P.; CLARK, Charles G.; SMITH, II, Leon M.; ORWAT, Michael J.; JEON, Yoon; CORTE, James R.; WO2014/160668; (2014); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

 

201150-73-4, tert-Butyl 5-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

5-amino-3,4-dihydro-1 H-isoquinoline-2-carboxylic acid teit-butyl ester (248 mg, 1 mmol) and carbonyl di-imidazole (165 mg, 1 mmol) were dissolved in DCM (5 mL) and DMF (2 mL). To the resulting mixture was added triethylamine (0.3 mL 2 mmol) and the sample was heated to 55 00 for 5 hours. After this time, imidazo[1 2- a]pyridine-3-carboxylic acid [5-((S)- 1-amino-ethyl) 2-methyl-phenyl]-amide hydrochloride (300 mg, 0.91 mmol) was added and the reaction heated at 55 00 overnight. The reaction was cooled and then evaporated to dryness, and the crude product was purified by silica chromatography with an eluting solvent of 0-15% methanol in DCM. The clean product eluted at approximately 8-10% methanol in DCM, which was collected and evaporated. The product was suspended in 4 M HCI in 1 ,4-dioxane (8 mL) and stirred overnight. The reaction was evaporated and purified by preparative HPLC to give a clean product from which the solvent was evaporated. The solid was evaporated in methanol (2 mL), and 1 M HCI in ether (Sm L) was added then the solvent was evaporated from the sample. The pale yellow solid was triturated with diethyl ether and dried in a vac-oven at 45 00 overnight to yield the title compound (144 mg), MS: [M+H] = 469., 201150-73-4

201150-73-4 tert-Butyl 5-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate 17750539, aisoquinoline compound, is more and more widely used in various.

Reference£º
Patent; ASTEX THERAPEUTICS LIMITED; SAXTY, Gordon; MURRAY, Christopher William; BERDINI, Valerio; PAGE, Lee William; ROOMANS, Susan; TAMANINI, Emiliano; BUCK, Ildiko Maria; DAY, James Edward Harvey; CARR, Maria Grazia; LEE, Lydia Yuen Wah; WO2015/4481; (2015); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem